Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation
Ana I. Duarte, Emanuel Candeias, Inês N. Alves, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1746-1746
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Giulia Bendotti, Laura Montefusco, Maria Elena Lunati, et al.
Pharmacological Research (2022) Vol. 182, pp. 106320-106320
Closed Access | Times Cited: 152
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Thian‐Sze Wong, Guangzhi Li, Shiliang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 63
Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages
Gabriela Dumitrița Stanciu, Veronica Bild, Daniela Carmen Ababei, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1713-1713
Open Access | Times Cited: 88
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 69
BACE1: More than just a β‐secretase
Hannah A. Taylor, Lena Przemyłska, Eva M. Clavane, et al.
Obesity Reviews (2022) Vol. 23, Iss. 7
Open Access | Times Cited: 65
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 51
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Dihe Cheng, Shuo Yang, Xue Zhao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 665-684
Open Access | Times Cited: 43
Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
Yixuan Wang, Hao Hu, Xinyu Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Puja Ghosh, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Theranostics (2023) Vol. 13, Iss. 14, pp. 4872-4884
Open Access | Times Cited: 25
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Muna A. Adem, Boris Decourt, Marwan N. Sabbagh
Biomedicines (2024) Vol. 12, Iss. 1, pp. 99-99
Open Access | Times Cited: 15
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 11
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways
Iwona Piątkowska‐Chmiel, Katarzyna Wicha-Komsta, Kamil Pawłowski, et al.
Cellular and Molecular Neurobiology (2025) Vol. 45, Iss. 1
Open Access | Times Cited: 1
GLP-1 mimetics and cognition
Habib Yaribeygi, Ali Rashidy‐Pour, Stephen L. Atkin, et al.
Life Sciences (2020) Vol. 264, pp. 118645-118645
Closed Access | Times Cited: 68
Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer’s Disease
Leela Paladugu, Abeer Gharaibeh, Nivya Kolli, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 860-860
Open Access | Times Cited: 55
Targeting Insulin Resistance to Treat Cognitive Dysfunction
Anit Tyagi, Subbiah Pugazhenthi
Molecular Neurobiology (2021) Vol. 58, Iss. 6, pp. 2672-2691
Open Access | Times Cited: 44
Diabetes and cognitive decline
Chiara Bellia, Mauro Lombardo, Marco Meloni, et al.
Advances in clinical chemistry (2022), pp. 37-71
Closed Access | Times Cited: 35
Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases
Shang‐Der Chen, Yao‐Chung Chuang, Tsu‐Kung Lin, et al.
European Journal of Pharmacology (2022) Vol. 938, pp. 175439-175439
Closed Access | Times Cited: 35
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Oestrogenic Regulation of Mitochondrial Dynamics
Siavash Beikoghli Kalkhoran, Georgios Kararigas
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1118-1118
Open Access | Times Cited: 29
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 17
Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease
Mingcui Zheng, Pengwen Wang
3 Biotech (2021) Vol. 11, Iss. 4
Open Access | Times Cited: 41
Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders
Qian Chen, Ting Cao, Nana Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 38
Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes
Gabriela Dumitrița Stanciu, Răzvan Nicolae Rusu, Veronica Bild, et al.
Biomedicines (2021) Vol. 9, Iss. 5, pp. 576-576
Open Access | Times Cited: 36
A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer’s Disease
Jessica Lynn, Mingi Park, Christiana Ogunwale, et al.
Journal of Alzheimer s Disease (2021) Vol. 85, Iss. 2, pp. 485-501
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top